Janux Therapeutics (JANX) Capital Expenditures (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Capital Expenditures of $273000.0 for Q1 2026, up 396.74% year-over-year from $54958.4 in Q1 2025, and up 122.51% quarter-over-quarter from -$1.2 million in Q4 2025.
Janux Therapeutics (JANX) Capital Expenditures (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Capital Expenditures for 7 consecutive years, with $273000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures rose 396.74% year-over-year to $273000.0; the TTM figure through Mar 2026 stood at $89000.0 (up 3.49% YoY), while the FY2025 annual figure was -$276000.0, down 173.6% from the prior year.
- Capital Expenditures improved to $273000.0 in Q1 2026 per JANX's latest filing, from -$1.2 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.5 million in Q2 2022 and bottomed at -$1.2 million in Q4 2025.
- Historically, Capital Expenditures has averaged $205411.8 across 5 years, with a median of $285000.0 in 2023.
- Annual changes were most pronounced in 2022 — Capital Expenditures sank 891.3% — and 2025, when it jumped 885.26%.
- Janux Therapeutics' Capital Expenditures stood at $313000.0 in 2022, then surged by 64.54% to $515000.0 in 2023, then plunged by 35.34% to $333000.0 in 2024, then tumbled by 464.26% to -$1.2 million in 2025, then jumped by 122.51% to $273000.0 in 2026.
- Business Quant data shows JANX's Capital Expenditures at $273000.0 in Q1 2026, -$1.2 million in Q4 2025, and $93000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | -861,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -861,000.00 |
| Jun 30, 2026 | -861,000.00 |
| Mar 31, 2026 | 273,000.00 |
| Mar 31, 2026 | 273,000.00 |
| Dec 31, 2025 | -1.21 Mn |
| Dec 31, 2025 | -1.21 Mn |
| Sep 30, 2025 | 93,000.00 |
| Sep 30, 2025 | 93,000.00 |
| Jun 30, 2025 | 936,000.00 |
| Jun 30, 2025 | 936,000.00 |
| Mar 31, 2025 | -92,000.00 |
| Mar 31, 2025 | -92,000.00 |
| Dec 31, 2024 | 333,000.00 |
| Dec 31, 2024 | 333,000.00 |
| Sep 30, 2024 | -250,000.00 |
| Sep 30, 2024 | -250,000.00 |
| Jun 30, 2024 | 95,000.00 |
| Jun 30, 2024 | 95,000.00 |
| Mar 31, 2024 | 197,000.00 |
| Mar 31, 2024 | 197,000.00 |